Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement From the American Heart Association

By M. Jaff, M. S. Mcmurtry, S. Archer, M. Cushman, N. Goldenberg, Samuel Z. Goldhaber, J. Jenkins, J. Kline, A. Michaels, P. Thistlethwaite and 3 more. Circulation, 2011

2,052 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Internal Medicine

View Paper: https://www.semanticscholar.org/paper/eb11cf949002e56fb628861679f820a422c2bbf1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. S. Rosenkranz
2. S. Schulman
3. Joshua A. Beckman

In Internal Medicine

1. M. Cushman
2. Samuel Z. Goldhaber
3. S. Konstantinides

Citations in the corpus

• COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up (2020, background): “Intermediate-risk hemodynamically stable patients (intermediate-low risk, or intermediate-high risk PE according to European Society of Cardiology [ESC] classification, submassive PE according to prior classifications) (49,87,91,94) should be managed initially with anticoagulation and close monitori”